

Correction

Correction: Döring et al. Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy. *Molecules* 2021, 26, 18

Henry Döring ¹, David Kreutzer ¹, Christoph Ritter ² and Andreas Hilgeroth ^{1,*}

¹ Research Group of Drug Development, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany; henry.doering@arcor.de (H.D.); david.kreutzer94@web.de (D.K.)

² Department of Clinical Pharmacy, Institute of Pharmacy, Ernst Moritz Arndt University Greifswald, 17489 Greifswald, Germany; ritter@uni-greifswald.de

* Correspondence: andreas.hilgeroth@pharmazie.uni-halle.de; Tel.: +49-345-55-25168

The authors would like to correct an error made through no fault of their own in the title paper [1]. The error is related to the *FAR* values in Table 1. In the earlier published version, the *FAR* values of compounds 15–21 were wrongly printed. So, they had to be corrected, from 1.19 to 1.12 for 15, 1.55 to 1.19 for 16, 0.95 to 1.55 for 17, 1.22 to 0.95 for 18, 0.98 to 1.22 for 19, 1.30 to 0.98 for 20 and 0.82 to 1.30 for 21. We provide below the corrected Table 1. The change has no influence on the reported results. The original article has been updated. The authors would like to apologize for any inconvenience caused to the readers by this change.



Citation: Döring, H.; Kreutzer, D.; Ritter, C.; Hilgeroth, A. Correction: Döring et al. Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy. *Molecules* 2021, 26, 18. *Molecules* 2022, 27, 3575. <https://doi.org/10.3390/molecules27113575>

Received: 11 March 2021

Accepted: 14 April 2022

Published: 2 June 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Table 1. MRP4 inhibition data of target compounds 4–21 with varied substitution patterns expressed as *FAR* values.

Compound	R ¹	R ²	Value ^[a]			<i>FAR</i>
			R ³	R ⁴		
4	CF ₃	H	CF ₃	H		1.28
5	CF ₃	H	OMe	H		1.21
6	CF ₃	H	H	OMe		1.11
7	CF ₃	H	OMe	OMe		1.10
8	H	CF ₃	OMe	H		1.28
9	H	CF ₃	H	OMe		1.11
10	H	CF ₃	OMe	OMe		1.26
11	F	F	OMe	H		1.43
12	F	F	H	OMe		1.40
13	F	F	OMe	OMe		1.23
14	F	H	OMe	OMe		1.21
15	H	F	OMe	OMe		1.12
16	CF ₃	OMe	CF ₃	H		1.19
17	CF ₃	OMe	OMe	H		1.55
18	CF ₃	OMe	H	OMe		0.95
19	CF ₃	OMe	OMe	OMe		1.22
20	OMe	OMe	CF ₃	H		0.98
21	OBn	OBn	CF ₃	H		1.30

^[a] Fluorescence activity ratio as mean of three determinations.

Reference

- Döring, H.; Kreutzer, D.; Ritter, C.; Hilgeroth, A. Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy. *Molecules* 2021, 26, 18. [[CrossRef](#)] [[PubMed](#)]